Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma

Autor: Johnson, DC, Weinhold, N, Mitchell, JS, Chen, B, Kaiser, M, Begum, DB, Hillengass, J, Bertsch, U, Gregory, WA, Cairns, D, Jackson, GH, Försti, A, Nickel, J, Hoffmann, P, Nöethen, MM, Stephens, OW, Barlogie, B, Davis, FE, Hemminki, K, Goldschmidt, H, Houlston, RS, Morgan, GJ

Publikováno v: Nature Communications

Survival following a diagnosis of multiple myeloma (MM) varies between patients and some of these differences may be a consequence of inherited genetic variation. In this study, to identify genetic markers associated with MM overall survival (MM-OS),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::e09f96198b35a956099b9a32a07f1911
https://eprints.whiterose.ac.uk/94466/1/ncomms10290.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.

Autor: Johnson DC; Division of Molecular Pathology, The Institute of Cancer Research, London SW7 3RP, UK., Weinhold N; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.; Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany., Mitchell JS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London SW7 3RP, UK., Chen B; German Cancer Research Center, 69121 Heidelberg, Germany., Kaiser M; Division of Molecular Pathology, The Institute of Cancer Research, London SW7 3RP, UK., Begum DB; Division of Molecular Pathology, The Institute of Cancer Research, London SW7 3RP, UK., Hillengass J; Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany., Bertsch U; Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany., Gregory WA; Leeds Institute of Molecular Medicine, Section of Clinical Trials Research, University of Leeds, Leeds LS2 9PH, UK., Cairns D; Leeds Institute of Molecular Medicine, Section of Clinical Trials Research, University of Leeds, Leeds LS2 9PH, UK., Jackson GH; Department of Haematology, Newcastle University, Newcastle-upon-Tyne NE1 7RU, UK., Försti A; German Cancer Research Center, 69121 Heidelberg, Germany.; Center for Primary Health Care Research, Lund University, 221 00 Malmö, Sweden., Nickel J; Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany., Hoffmann P; Institute of Human Genetics, University of Bonn, D-53127 Bonn, Germany.; Division of Medical Genetics, Department of Biomedicine, University of Basel, 4031 Basel, Switzerland., Nöethen MM; Institute of Human Genetics, University of Bonn, D-53127 Bonn, Germany.; Department of Genomics, Life &Brain Center, University of Bonn, D-53127 Bonn, Germany., Stephens OW; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA., Barlogie B; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA., Davis FE; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA., Hemminki K; German Cancer Research Center, 69121 Heidelberg, Germany.; Center for Primary Health Care Research, Lund University, 221 00 Malmö, Sweden., Goldschmidt H; Department of Internal Medicine V, University of Heidelberg, 69120 Heidelberg, Germany.; National Center of Tumor Diseases, 69120 Heidelberg, Germany., Houlston RS; Division of Molecular Pathology, The Institute of Cancer Research, London SW7 3RP, UK.; Division of Genetics and Epidemiology, The Institute of Cancer Research, London SW7 3RP, UK., Morgan GJ; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA.

Publikováno v: Nature communications [Nat Commun] 2016 Jan 08; Vol. 7, pp. 10290. Date of Electronic Publication: 2016 Jan 08.